INTERVENTIONAL FLASHLIGHT

DOI: 10.4244/EIJ-D-17-00081

Five-year follow-up of underexpanded and overexpanded bioresorbable scaffolds: self-correction and impact on shear stress

Ryo Torii1, PhD; Erhan Tenekecioglu2, MD; Christos Bourantas3,4, MD, PhD; Eric Poon5, PhD; Vikas Thondapu5,6, MD; Frank Gijsen7, PhD; Yohei Sotomi8, MD; Yoshinobu Onuma2, MD, PhD; Peter Barlis6, MD, PhD; Andrew S.H. Ooi5, PhD; Patrick W. Serruys2,9*, MD, PhD

Two patients received 3.0×18 mm Absorb™ bioresorbable vascular scaffolds (Abbott Vascular, Santa Clara, CA, USA), one in the left anterior descending coronary artery, the other in the circumflex coronary artery. Post-implantation OCT (pullback speed: 20 mm/s, acquisition rate: 200 frames/s) and angiographic data were fused to reconstruct the coronary anatomy, and computational fluid dynamic (CFD) techniques were used to simulate Newtonian steady blood flow and estimate endothelial shear stress (ESS) distributions1. Panels A, B, C & P1 show underexpansion of the scaffold (mean expansion index: 0.51). Panels D, E, F & P2 show an overexpanded bioresorbable scaffold (mean expansion index: 1.32).

In the CFD model of the underexpanded case (Panel C), high ESS (in red) was noted on top of the struts which disrupted the flow, creating recirculation zones and low ESS (in dark blue) in the inter-strut zones. Scaffold underexpansion caused a “step-down” at the proximal edge of the scaffolded segment (Panel P1, black box in Panel C). On the five-year OCT, there was attenuation of the step-down appearance with normalised ESS in the proximal edge segment (Panels A’, B’ , C’ & P1’); the luminal surface was smoother and overall the shear stress was more homogeneous and physiological (1.5-3.0 Pa).

In the CFD model of the overexpanded case, low ESS was detected not only in the inter-strut areas but also on top of the struts. Scaffold overexpansion caused a “step-up” at the proximal edge of the scaffolded segment. At the five-year follow-up, the step-up became less prominent and the areas of very low shear stress regressed considerably (Panels D’, E’, F’ & P2’).

These two cases of overexpansion and underexpansion at baseline resulted acutely in two different shear stress distributions. Both increased and decreased ESS appear to induce a biological mechano-transduction process that aims at normalising ESS levels at long-term follow-up to values close to the physiological ranges (1.5-2.5 Pa). The mechanism of “normalisation” seems to be related to a dynamic remodelling, which presumably resulted from shear stress, wall stress, cyclic strain and other important biologic factors2,3.

Practical implication

Underexpansion and overexpansion have been incriminated as causative factors of adverse cardiac events. However, dynamic biological interaction between vessel wall and scaffold may attenuate the adverse haemodynamic impact of overexpansion or underexpansion.

Guest Editor

This paper was guest edited by Lorenz Räber, MD, PhD; Department of Cardiology, Swiss Cardiovascular Center, University Hospital Bern, Switzerland.

Conflict of interest statement

P.W. Serruys and Y. Onuma are members of the International Advisory Board of Abbott Vascular. The other authors have no conflicts of interest to declare. The Guest Editor has no conflicts of interest to declare.

Volume 12 Number 17
Apr 20, 2017
Volume 12 Number 17
View full issue


Key metrics

Suggested by Cory

EXPERIMENTAL RESEARCH

10.4244/EIJY15M07_02 Mar 18, 2016
Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-expansion experiments
Foin N et al
free
Trending articles
334.7

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
84.05

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
44.9

State-of-the-Art

10.4244/EIJ-D-25-01346 May 4, 2026
Slow flow and no reflow after percutaneous coronary intervention
Brugaletta S et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
38.2

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
32.7

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
29.8

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
29.2

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
29.2

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved